{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:53:43Z","timestamp":1781114023435,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) secondary to PARP inhibitors (PARPi), based on the line of treatment, in real-world ovarian cancer (OC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the TriNetX platform, we compared a cohort (experimental A) of 3402 OC patients treated with first-line maintenance PARPi to a control cohort of 1653 OC patients treated with platinum-based chemotherapy without PARPi. Experimental group B included 356 OC patients treated with PARPi after a platinum-sensitive relapse and was compared to a control cohort of 1503 patients who had not received PARPi after 2 lines of platinum-based chemotherapy. The cohorts were propensity score matched (PSM) 1:1 (experimental A vs control 1 and experimental B vs control 2) for age, race, bevacizumab treatment, and genetic susceptibility to neoplasms. A hazard ratio (HR) was used to compare the incidence of MDS and AML between the matched cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the first-line setting, 2 groups of 1346 matched OC patients (mean age 59.8 \u00b1 10.2 SD) were evaluated. The overall incidence of MDS or AML was 1.9% and 0.1% in the experimental A and control groups, respectively (HR\u2009=\u20092.46; 95% CI 1.27-4.75, P\u2009=\u2009.006). For the platinum-\u00adsensitive relapse setting, the HR was 1.76 (95% CI 0.42-7.37, P\u2009=\u2009.432). No significant differences were observed between the various PARPi used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study indicates that PARPi may increase the risk of MDS or AML after first-line maintenance treatment. No significant differences were found across the types of PARPi used.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf243","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:56:59Z","timestamp":1754049419000},"source":"Crossref","is-referenced-by-count":2,"title":["Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-8041","authenticated-orcid":false,"given":"Alberto","family":"Farolfi","sequence":"first","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gentili","sequence":"additional","affiliation":[{"name":"Outcome Research, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Testoni","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rusconi","sequence":"additional","affiliation":[{"name":"TriNetX, LLC , Cambridge, MA 02140,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Montanari","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema Hernandez","family":"Ibarburu","sequence":"additional","affiliation":[{"name":"TriNetX, LLC , Cambridge, MA 02140,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025110501301690900_oyaf243-B1","doi-asserted-by":"crossref","first-page":"990048","DOI":"10.3389\/fphar.2022.990048","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia following the use of Poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025110501301690900_oyaf243-B2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2025110501301690900_oyaf243-B3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025110501301690900_oyaf243-B4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025110501301690900_oyaf243-B5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.21873\/anticanres.16202","article-title":"Real-World data on olaparib in relapsed BRCA-mutated ovarian cancer: a multicenter GINECO RETROLA cohort study","volume":"43","author":"Bourien","year":"2023","journal-title":"Anticancer Res"},{"key":"2025110501301690900_oyaf243-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2024.01.022","article-title":"Real world data of niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group","volume":"184","author":"Musacchio","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025110501301690900_oyaf243-B7","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025110501301690900_oyaf243-B8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025110501301690900_oyaf243-B9","doi-asserted-by":"crossref","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025110501301690900_oyaf243-B10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"2025110501301690900_oyaf243-B11","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025110501301690900_oyaf243-B12","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3390\/cancers13246385","article-title":"PARP inhibitors and myeloid neoplasms: a double-edged sword","volume":"13","author":"Csizmar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025110501301690900_oyaf243-B13","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2025110501301690900_oyaf243-B14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"2025110501301690900_oyaf243-B15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"2025110501301690900_oyaf243-B16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2025110501301690900_oyaf243-B17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025110501301690900_oyaf243-B18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2025110501301690900_oyaf243-B19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2025110501301690900_oyaf243-B20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/s41375-024-02253-3","article-title":"Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer [published correction appears in","volume":"38","author":"Arends","year":"2024","journal-title":"Leukemia"},{"key":"2025110501301690900_oyaf243-B21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.annonc.2021.04.015","article-title":"Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"key":"2025110501301690900_oyaf243-B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf243\/63961249\/oyaf243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf243\/63961249\/oyaf243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf243\/63961249\/oyaf243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:30:25Z","timestamp":1762324225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf243\/8222741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf243","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,5]]},"article-number":"oyaf243"}}